MedElevator
Войти в исследования Endocrinology, diabetes & metabolism · 2026
Neuropeptide Alterations in Type 2 Diabetes Mellitus: A Meta-Analysis of Circulating Spexin and Galanin Levels.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mahat Roshan Kumar, Yadav Sushil, Naaz Kahkashan, Sah Nand Kishor Prasad, Kushwaha Amrendra P
Аннотация
BACKGROUND: Spexin and galanin are neuropeptides involved in glucose homeostasis, insulin sensitivity, appetite, and energy metabolism. We conducted a systematic review and meta-analysis to synthesise evidence on circulating spexin and galanin concentrations in patients with type 2 diabetes mellitus (T2DM).
METHODS: PubMed/MEDLINE, Scopus, and Web of Science were systematically searched from inception to March 22, 2026. Observational studies reporting circulating spexin and/or galanin levels in adults with T2DM and non-diabetic controls were included. Random-effects meta-analyses were performed to calculate pooled standardised mean differences (SMDs) with 95% confidence intervals (CIs). Subgroup analyses, meta-regression, sensitivity analyses, prediction intervals, and publication bias assessments were conducted.
RESULTS: Nineteen studies met the inclusion criteria. Thirteen studies (1453 T2DM and 850 controls) showed significantly lower circulating spexin levels in T2DM (SMD = -2.37, 95% CI: -3.21 to -1.53; p < 0.0001), with substantial heterogeneity (I2 = 98.3%). Four studies further showed reduced spexin levels in patients with diabetic complications compared with uncomplicated T2DM (SMD = -1.12, 95% CI: -1.75 to -0.49; p = 0.0005). Meta-regression identified age as a significant moderator (p = 0.007), whereas BMI, HbA1c, sex, and publication year were not significant. Four studies (171 T2DM and 172 controls) revealed significantly elevated circulating galanin levels in T2DM (SMD = 1.35, 95% CI: 1.02-1.68; p < 0.0001) with moderate heterogeneity (I2 = 47.2%).
CONCLUSIONS: Circulating spexin levels are significantly decreased, whereas galanin levels are significantly increased in T2DM. These neuropeptides show potential as biomarkers of metabolic dysregulation and diabetic complications; however, the findings should be interpreted with caution owing to the very low certainty of the available evidence.
METHODS: PubMed/MEDLINE, Scopus, and Web of Science were systematically searched from inception to March 22, 2026. Observational studies reporting circulating spexin and/or galanin levels in adults with T2DM and non-diabetic controls were included. Random-effects meta-analyses were performed to calculate pooled standardised mean differences (SMDs) with 95% confidence intervals (CIs). Subgroup analyses, meta-regression, sensitivity analyses, prediction intervals, and publication bias assessments were conducted.
RESULTS: Nineteen studies met the inclusion criteria. Thirteen studies (1453 T2DM and 850 controls) showed significantly lower circulating spexin levels in T2DM (SMD = -2.37, 95% CI: -3.21 to -1.53; p < 0.0001), with substantial heterogeneity (I2 = 98.3%). Four studies further showed reduced spexin levels in patients with diabetic complications compared with uncomplicated T2DM (SMD = -1.12, 95% CI: -1.75 to -0.49; p = 0.0005). Meta-regression identified age as a significant moderator (p = 0.007), whereas BMI, HbA1c, sex, and publication year were not significant. Four studies (171 T2DM and 172 controls) revealed significantly elevated circulating galanin levels in T2DM (SMD = 1.35, 95% CI: 1.02-1.68; p < 0.0001) with moderate heterogeneity (I2 = 47.2%).
CONCLUSIONS: Circulating spexin levels are significantly decreased, whereas galanin levels are significantly increased in T2DM. These neuropeptides show potential as biomarkers of metabolic dysregulation and diabetic complications; however, the findings should be interpreted with caution owing to the very low certainty of the available evidence.